During the late 1990s, scientists in several countries announced plans to construct genomic databases, or ‘biobanks’, from material provided by patients, volunteers and the general public. In Britain, Estonia, Tonga, Sweden and Iceland, amongst other places, researchers promised that the data obtained from samples and medical records would uncover the genetic bases of many diseases, and would ultimately be used to develop new diagnostic and therapeutic products. These efforts relied on new automated technologies that simplified the processing of genetic material and the storage of vast amounts of information. They were also underpinned by the growing commercial ethos in biology; many projects were undertaken by new ‘start-up’ companies bankrolled by large firms and private investors who envisaged significant financial returns. Progress was covered in the Wall Street Journal as much as in Nature.
Mike Fortun's excellent Promising Genomics is the first book-length study of the most high-profile and contentious of these recent endeavours. It covers the period from 1998 to 2003 and details the controversy surrounding the Icelandic parliament's plan to give deCODE Genetics, an Iceland-based company, exclusive permission to construct and access a centralized database established from the health records of every Icelander. As Fortun argues, the Icelandic case offers an excellent window into the promissory mindset behind the burgeoning genomic economy. He shows how deCODE, and specifically its charismatic CEO Kari Stefansson, promised to utilize the (supposedly) homogeneous Icelandic population to uncover the genes involved in many common diseases and develop drugs that, in turn, it offered to make free to every Icelander. By thus promising significant financial and therapeutic returns from this work, deCODE courted favour with politicians, who in turn passed the so-called Health Sector Database Bill; with commercial firms like Hoffman LaRoche, who signed deals worth around $200 million; and with private investors, who invested heavily in deCODE shares when it was floated on the NASDAQ stock market. But, as Fortun highlights, deCODE's activities also prompted significant criticism. Opponents of the Health Sector Database formed a group, Mannvernd (meaning ‘Human Protection’), to protest the enactment of presumed consent, whereby the health records of the entire population were automatically included unless an individual explicitly objected. By March 2001 Mannvernd's campaign had convinced over 20,000 patients to opt out of the database. And in 2003, following a legal challenge, the Icelandic Supreme Court ruled that plans for the Health Sector Database were unconstitutional.
But Promising Genomics is more than just a company history – or even a history of genomic science. Thanks to Fortun's anthropological skills, it is also a convincing ethnography of modern Iceland. Fortun details how, after being persuaded by the Icelandic historian of science Skuli Sigurdsson, he made several trips to Iceland, where he shadowed Kari Stefansson, various politicians and members of Mannvernd. And he skilfully combines accounts of these meetings with observations on Icelandic culture, passages from the novels of Haldor Laxness and more general historical background in order to locate genomic science as one of several factors implicated in the construction of Iceland as a modern, cosmopolitan nation. Fortun shows how the efforts to establish the Health Sector Database relied upon – and were attempts to position Iceland within – globally dispersed networks of capital, genes, technology and political relations. At the same time, he shows how deCODE, like the government and the tourist industry, sought to attract investment by mobilizing long-standing Icelandic myths of remoteness and otherness, selling its people as a perfect genetic resource on account of their supposed isolation from the rest of Europe.
Inventively written and thoroughly entertaining, Promising Genomics deserves a wide audience. The deCODE strategy that Fortun outlines encapsulates the grand ambition and ethical tensions inherent in modern genomics. It implicated a whole nation, involved vast sums of money, and also raised questions regarding the nature of consent and the transformation of personal data into a financial commodity. For these reasons, many students and academics have long followed the Icelandic situation and will already be familiar with Fortun's work on deCODE. By expanding on this work, especially by situating deCODE amidst the broader histories of Iceland and venture capital, Promising Genomics is a welcome addition to several academic literatures, including those in the history of science, anthropology and bioethics. But perhaps its greatest relevance lies in the way it dissects the speculative financial mindset that recently brought the world economy, and Iceland in particular, to the brink of bankruptcy. Fortun's concluding plea for due diligence, urging us all to separate good promises from bad, has never been more apposite.
